Related Experiment Videos

[Creutzfeldt-Jakob disease and transfusional risk: the point in 1998]

S Laperche1

  • 1Laboratoire de virologie transfusionnelle, Institut national de la transfusion sanguine, Paris.

Insights

Creutzfeldt-Jakob disease (CJD) transmission via blood transfusion is a theoretical risk. Current measures include excluding at-risk donors and leukocyte depletion, with ongoing surveillance for new variant CJD (nvCJD).

Area of Science:

  • Neuroscience
  • Transfusion Medicine
  • Epidemiology

Background:

  • Iatrogenic and experimental transmission of Creutzfeldt-Jakob disease (CJD) are established.
  • The potential for CJD transmission through blood transfusion due to contaminated blood components is a significant concern.
  • Emerging research indicates a potential role for B lymphocytes in CJD pathogenesis.

Purpose of the Study:

  • To assess the risk of CJD transmission via blood transfusion.
  • To review current strategies for mitigating transfusion-related CJD.
  • To highlight the importance of surveillance for new variant CJD (nvCJD).

Main Methods:

  • Review of existing epidemiological and experimental data on CJD transmission.
  • Analysis of the role of B lymphocytes in CJD.
  • Evaluation of current blood safety measures, including donor exclusion and leukocyte depletion.

Main Results:

  • No definitive epidemiological evidence currently links classical CJD transmission to B lymphocytes.
  • Theoretical risk of transfusion-transmitted CJD persists.
  • New variant CJD (nvCJD) shows tropism for lymphoreticular tissues, necessitating vigilance.

Conclusions:

  • Exclusion of at-risk blood donors and leukocyte depletion are key preventive measures against transfusion-transmitted CJD.
  • Continued surveillance for nvCJD is crucial due to its association with lymphoreticular tissues.
  • The absence of a biological marker for CJD underscores the importance of these precautionary strategies.

Related Concept Videos